The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Abstract
The Gynecologic Oncology Group has conducted a randomized prospective trial comparing cisplatin 50 mg/m2 every 21 days (regimen 1), 100 mg/m2 every 21 days (regimen 2), and cisplatin 20 mg/m2 for five consecutive days repeated every 21 days (regimen 3). Four hundred ninety-seven evaluable patients have been accrued on this study. The response rates were 20.7%, 31.4%, and 25.0%, for regimens 1, 2, and 3, respectively; the complete remission rates were 10.0%, 12.7%, and 8.6% for regimens 1, 2, and 3, respectively. The median duration of response ranged from 3.9 to 4.8 months, the median progression-free interval from 3.7 to 4.6 months, and the median survival time from 6.1 to 7.1 months. The difference in response rates for regimens 1 and 2 is statistically significant (P = .015) but less than the magnitude originally considered clinically significant. The differences in complete remission rates, response duration, progression-free interval, and survival times are not statistically significant. The following types of toxicity were observed: serum creatinine level greater than 2 mg/dL and/or BUN level greater than 40 mg/dL was 7%, 14%, and 17% on regimens 1, 2, and 3, respectively; leukocyte count less than 4,000/microL was 27%, 44%, and 41% on regimens 1, 2, and 3, respectively. Nausea and vomiting occurred in 74 patients (83%). The regimen consisting of a 100-mg/m2 single dose has produced a statistically significant higher response rate than the 50 mg/m2 regimen while producing no appreciable differences in complete remission rate, response duration, progression-free interval, or survival. In addition, the higher dose regimen was associated with greater myelosuppression and nephrotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
Dose: A critical factor in cancer chemotherapy
Frei, E., & Canellos, G. P. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90472-6 · Cited by 839
High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresis
Hayes, D. M., Cvitkovic, E., Golbey, R. B., Scheiner, E., Helson, L., & Krakoff, I. H. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j · Cited by 626
CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck.
Wittes, R. E., Cvitkovic, E., Shah, J., Gerold, F. P., & Strong, E. W. (1977) · PubMed · Cited by 156
Thigpen, T., Shingleton, H. M., Homesley, H. D., Lagasse, L. D., & Blessing, J. A. (1979) · PubMed · Cited by 74
Self-citation
Cited by
Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, C. L., Walker, J. L., & Gersell, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401503 · Cited by 1,923
Self-citationWhitney, C. W., Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, Jr., Clarke-Pearson, D. L., & Liao, S.-Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1339 · Cited by 1,524
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Moore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.170 · Cited by 635
Self-citation
Metadata
- Authors
- Bonomi, P., Blessing, J. A., Stehman, F. B., DiSaia, P. J., Walton, L., & Major, F. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1985-08
- Volume
- 3
- Issue
- 8
- Pages
- 1079-1085
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1926137745
- Cited by
- 402
- References
- 8
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. https://app.cochat.ai/papers/10.1200/jco.1985.3.8.1079
- The paper
- Bonomi, P., Blessing, J. A., Stehman, F. B., DiSaia, P. J., Walton, L., & Major, F. J. (1985). Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1985.3.8.1079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.